The company has entered a material transfer agreement with the Josep Carreras Leukaemia Research Institute (JCLRI) in Spain for use of the company’s iTANK platform in arming CAR T-cells for the treatment of Ewing Sarcoma.
The agreement is the first to be executed as part of Elicera’s strategy of finding collaborators and licensing partners for iTANK, it states.
“Supporting research that gets us closer to an approved CAR T-cell therapy for use in solid tumors is important to us at Elicera.”
“A central part of Elicera’s strategy for iTANK is entering into partnerships like this. With the first agreement in the books – and hopefully more to be established – we have achieved an important company milestone,” said Jamal El-Mosleh, CEO of Elicera, in the press release. “We are thrilled that iTANK’s potential to increase the efficacy of CAR T-cell therapies in solid tumors has caught the eye of highly respected research institutions like the JCLRI. Supporting research that gets us closer to an approved CAR T-cell therapy for use in solid tumors is important to us at Elicera. We look forward to supporting the JCLRI in their quest to identify an innovative treatment option for Ewing Sarcoma, whose difficult to treat solid tumors have given rise to an urgent demand for new therapeutic approaches.”
An efficacious and safe innovative approach
Following a comprehensive analysis of potentially efficient and safe targets for Ewing Sarcoma, the JCLRI has hypothesized that the generation of CAR T-cells, armed with the iTANK platform and their ability to elicit a multi-targeted attack on solid tumors, can represent an efficacious and safe innovative approach for treatment of metastasized Ewing Sarcoma, Elicera states.
The agreement does not grant the JCLRI any intellectual property rights to the iTANK-platform, and any patentable inventions arising from the project shall become the joint property of Elicera and the JCLRI.
Photo of Jamal El-Mosleh, CEO of Elicera